Global impacts of COVID-19 infection in patients with Parkinson's disease: an integrative review

Authors

DOI:

https://doi.org/10.33448/rsd-v10i1.12043

Keywords:

Pandemics; Coronavirus infections; Parkinson disease.

Abstract

The pandemic Coronavirus 2019-nCoV (COVID-19) outbreak is target of research to understand its consequences in patients with neurological diseases, such as Parkinson's disease. This article aims to discuss the evidence in scientific literature about the risks and complications of the COVID-19 pandemic on Parkinson's patients. Searches for articles in English, Portuguese or Spanish were carried out using the PubMed, PubMed, Lilacs, ScienceDirect and SciElo databases, using the associated descriptors: “Coronavirus Infections” OR “COVID-19”AND “Parkinson Disease” about years 2019 and 2020. 268 results were found that, after applying inclusion and exclusion criteria, were reduced to 23 articles. The analysis indicates that the pandemic contributes to psychological stress and is related to the worsening of non-motor and motor symptoms. Symptoms are aggravated by difficulties in health care access, access to medications and maintenance of specialized treatments. In patients with COVID-19 infection, this can lead to immune dysregulation, neuronal death and changes in dopaminergic metabolism, in addition to inflammatory activation that could worsen synucleinopathy. Parkinson's disease itself does not represent an increased risk of infection, however the average age of patients and comorbidities in this group are factors that increase the chances of hospitalization and death after contracting COVID-19. In this perspective, protective strategies such as physical exercise, physiotherapy, psychosocial dynamics and telemedicine tools are essential and must be adapted to promote health care in times of isolation.

References

Adhikari, S. P., Meng, S., Wu, Y.-J., Mao, Y.-P., Ye, R.-X., Wang, Q.-Z., Sun, C., Sylvia, S., Rozelle, S., & Raat, H. (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infectious diseases of poverty, 9(1), 1–12. https://doi.org/10.1186/s40249-020-00646-x

Antonini, A., Leta, V., Teo, J., & Chaudhuri, K. R. (2020). Outcome of Parkinson’s Disease Patients Affected by COVID-19. Movement Disorders: Official Journal of the Movement Disorder Society, 35(6), 905–908. https://doi.org/10.1002/mds.28104

Beyea, S., & Nichll, L. H. (1998). Writing an integrative review. AORN journal, 67(4), 877–881. https://doi.org/10.1016/s0001-2092(06)62653-7

Bhidayasiri, R., Virameteekul, S., Kim, J.-M., Pal, P. K., & Chung, S.-J. (2020). COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson’s Disease Patient Care. Journal of Movement Disorders, 13(2), 105–114. https://doi.org/10.14802/jmd.20042

Brasil, M. da S. (2020). Protocolo de Manejo Clínico para o Novo Coronavírus (2019-nCoV). https://www.gov.br/saude/pt-br/media/pdf/2021/janeiro/07/boletim_epidemiologico_covid_44.pdf

Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M. (2020a). The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease. Journal of Parkinson’s disease, Preprint, 1–13. https://doi.org/10.3233/jpd-202249

Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M. (2020b). The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-202249

Brugger, F., Erro, R., Balint, B., Kägi, G., Barone, P., & Bhatia, K. P. (2015). Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view. npj Parkinson’s Disease, 1(1), 1–5. https://doi.org/10.1038/npjparkd.2015.14

Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., & Wang, H. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. Bmj, 368. https://doi.org/10.1136/bmj.m1091

Cheong, J. L.-Y., Goh, Z. H. K., Marras, C., Tanner, C. M., Kasten, M., Noyce, A. J., & Movement Disorders Society Epidemiology Study Group. (2020). The Impact of COVID-19 on Access to Parkinson’s Disease Medication. Movement Disorders: Official Journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28293

Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020). Effects of COVID-19 on Parkinson’s Disease Clinical Features: A Community-Based Case-Control Study. Movement Disorders: Official Journal of the Movement Disorder Society, 35(8), 1287–1292. https://doi.org/10.1002/mds.28170

D’Avolio, A., Avataneo, V., Manca, A., Cusato, J., De Nicolò, A., Lucchini, R., Keller, F., & Cantù, M. (2020). 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients, 12(5), 1359. https://doi.org/10.3390/nu12051359

de Marcaida, J. A., Lahrmann, J., Machado, D., Bluth, L., Dagostine, M., Moro-de Casillas, M., Bortan, E., Kanchana, S., & Alberts, M. (2020). Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center. Geriatrics (Basel, Switzerland), 5(3). https://doi.org/10.3390/geriatrics5030054

Del Prete, E., Francesconi, A., Palermo, G., Mazzucchi, S., Frosini, D., Morganti, R., Coleschi, P., Raglione, L. M., Vanni, P., Ramat, S., Novelli, A., Napolitano, A., Battisti, C., Giuntini, M., Rossi, C., Menichetti, C., Ulivelli, M., De Franco, V., Rossi, S., … Tuscany Parkinson COVID-19 Participants. (2020). Prevalence and impact of COVID-19 in Parkinson’s disease: Evidence from a multi-center survey in Tuscany region. Journal of Neurology. https://doi.org/10.1007/s00415-020-10002-6

Elbeddini, A., To, A., Tayefehchamani, Y., & Wen, C. (2020). Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic. Journal of Clinical Movement Disorders, 7, 7. https://doi.org/10.1186/s40734-020-00089-4

Fasano, A., Antonini, A., Katzenschlager, R., Krack, P., Odin, P., Evans, A. H., Foltynie, T., Volkmann, J., & Merello, M. (2020a). Management of Advanced Therapies in Parkinson’s Disease Patients in times of Humanitarian crisis: The COVID-19 experience. Movement Disorders Clinical Practice, 7(4), 361–372. https://doi.org/10.1002/mdc3.12965

Fasano, A., Antonini, A., Katzenschlager, R., Krack, P., Odin, P., Evans, A. H., Foltynie, T., Volkmann, J., & Merello, M. (2020b). Management of Advanced Therapies in Parkinson’s Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. Movement Disorders Clinical Practice, 7(4), 361–372. https://doi.org/10.1002/mdc3.12965

Fasano, A., Cereda, E., Barichella, M., Cassani, E., Ferri, V., Zecchinelli, A. L., & Pezzoli, G. (2020). COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy. Movement Disorders: Official Journal of the Movement Disorder Society, 35(7), 1089–1093. https://doi.org/10.1002/mds.28176

Fasano, A., Elia, A. E., Dallocchio, C., Canesi, M., Alimonti, D., Sorbera, C., Alonso-Canovas, A., & Pezzoli, G. (2020). Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism & Related Disorders, 78, 134–137. https://doi.org/10.1016/j.parkreldis.2020.08.012

Ferini-Strambi, L., & Salsone, M. (2020). COVID-19 and neurological disorders: Are neurodegenerative or neuroimmunological diseases more vulnerable? Journal of Neurology. https://doi.org/10.1007/s00415-020-10070-8

Gal-Tanamy, M., Bachmetov, L., Ravid, A., Koren, R., Erman, A., Tur-Kaspa, R., & Zemel, R. (2011). Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology, 54(5), 1570–1579. https://doi.org/10.1002/hep.24575

Garg, S. (2020). Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR. Morbidity and mortality weekly report, 69. http://dx.doi.org/10.15585/mmwr.mm6915e3

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., & Hui, D. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708–1720. https://doi.org/10.1056/NEJMoa2002032

Hainque, E. (2020). Rapid worsening in Parkinson’s disease may hide COVID-19 infection. Parkinsonism & Related Disorders. https://dx.doi.org/10.1016%2Fj.parkreldis.2020.05.008

Hall, M.-F. E., & Church, F. C. (2020). Exercise for Older Adults Improves the Quality of Life in Parkinson’s Disease and Potentially Enhances the Immune Response to COVID-19. Brain Sciences, 10(9). https://doi.org/10.3390/brainsci10090612

Hamer, M., Kivimäki, M., Gale, C. R., & Batty, G. D. (2020). Lifestyle Risk Factors for Cardiovascular Disease in Relation to COVID-19 Hospitalization: A Community-Based Cohort Study of 387,109 Adults in UK. medRxiv. https://dx.doi.org/10.1101%2F2020.05.09.20096438

Helmich, R. C., & Bloem, B. R. (2020). The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. Journal of Parkinson’s disease, 10(2), 351. https://dx.doi.org/10.3233%2FJPD-202038

Hribar, C. A., Cobbold, P. H., & Church, F. C. (2020). Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease. Brain Sciences, 10(5). https://doi.org/10.3390/brainsci10050284

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., & Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Ilie, P. C., Stefanescu, S., & Smith, L. (2020). The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research, 1–4. https://doi.org/10.1007/s40520-020-01570-8

Jarcho, J. A., Ingelfinger, J. R., Hamel, M. B., D’Agostino Sr, R. B., & Harrington, D. P. (2020). Inhibitors of the renin–angiotensin–aldosterone system and Covid-19. https://doi.org/10.1056/NEJMe2012924

Little, P. (2020). Non-steroidal anti-inflammatory drugs and covid-19. https://doi.org/10.1136/bmj.m1185

Martin, S. A., Pence, B. D., & Woods, J. A. (2009). Exercise and respiratory tract viral infections. Exercise and sport sciences reviews, 37(4), 157. https://dx.doi.org/10.1097%2FJES.0b013e3181b7b57b

Miele, G., Straccia, G., Moccia, M., Leocani, L., Tedeschi, G., Bonavita, S., Lavorgna, L., & Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology. (2020). Telemedicine in Parkinson’s Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. Telemedicine Journal and E-Health: The Official Journal of the American Telemedicine Association. https://doi.org/10.1089/tmj.2020.0184

Monteiro, L., Souza-Machado, A., Valderramas, S., & Melo, A. (2012). The effect of levodopa on pulmonary function in Parkinson’s disease: A systematic review and meta-analysis. Clinical therapeutics, 34(5), 1049–1055. https://doi.org/10.1016/j.clinthera.2012.03.001

Moreno López, C. L., Bernal-Pacheco, Ó., Barrios Vincos, G., Cerquera Cleves, S. C., Moreno López, C. L., Bernal-Pacheco, Ó., Barrios Vincos, G., & Cerquera Cleves, S. C. (2020). Parkinson disease and COVID-19: Two pandemics at once. Acta Neurológica Colombiana, 36, 39–46. https://doi.org/10.22379/24224022292

Nataf, S. (2020). An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. Journal of medical virology. https://doi.org/10.1002/jmv.25826

O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., & Hüttenhain, R. (2020). A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. https://doi.org/10.1038/s41586-020-2286-9

Papa, S. M., Brundin, P., Fung, V. S. C., Kang, U. J., Burn, D. J., Colosimo, C., Chiang, H.-L., Alcalay, R. N., Trenkwalder, C., & MDS-Scientific Issues Committee. (2020). Impact of the COVID-19 Pandemic on Parkinson’s Disease and Movement Disorders. Movement Disorders: Official Journal of the Movement Disorder Society, 35(5), 711–715. https://doi.org/10.1002/mds.28067

Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. bmj, 369. https://doi.org/10.1136/bmj.m1966

Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018). The physical activity guidelines for Americans. Jama, 320(19), 2020–2028. https://doi.org/10.1001/jama.2018.14854

Prasad, S., Holla, V. V., Neeraja, K., Surisetti, B. K., Kamble, N., Yadav, R., & Pal, P. K. (2020a). Parkinson’s Disease and COVID-19: Perceptions and Implications in Patients and Caregivers. Movement Disorders: Official Journal of the Movement Disorder Society, 35(6), 912–914. https://doi.org/10.1002/mds.28088

Prasad, S., Holla, V. V., Neeraja, K., Surisetti, B. K., Kamble, N., Yadav, R., & Pal, P. K. (2020b). Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson’s Disease. Neurology India, 68(4), 792–795. https://doi.org/10.4103/0028-3886.293472

Rajan, S., Kaas, B., & Moukheiber, E. (2019). Movement disorders emergencies. Seminars in neurology, 39(01), 125–136. https://doi.org/10.1055/s-0038-1677050

Rogers, J. P., Chesney, E., Oliver, D., Pollak, T. A., McGuire, P., Fusar-Poli, P., Zandi, M. S., Lewis, G., & David, A. S. (2020). Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(20)30203-0

Roland, K. P., Cornett, K. M., Theou, O., Jakobi, J. M., & Jones, G. R. (2012). Concurrence of Frailty and Parkinson’s Disease. The Journal of Frailty & Aging, 1(3), 123–127. https://doi.org/10.14283/jfa.2012.20

Santos-García, D., Oreiro, M., Pérez, P., Fanjul, G., Paz González, J. M., Feal Painceiras, M. J., Cores Bartolomé, C., Valdés Aymerich, L., García Sancho, C., & Castellanos Rodrigo, M. D. M. (2020). Impact of Coronavirus Disease 2019 Pandemic on Parkinson’s Disease: A Cross-Sectional Survey of 568 Spanish Patients. Movement Disorders: Official Journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28261

Schirinzi, T., Cerroni, R., Di Lazzaro, G., Liguori, C., Scalise, S., Bovenzi, R., Conti, M., Garasto, E., Mercuri, N. B., Pierantozzi, M., Pisani, A., & Stefani, A. (2020). Self-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(6), 1373–1375. https://doi.org/10.1007/s10072-020-04442-1

Schirinzi, T., Landi, D., & Liguori, C. (2020). COVID-19: Dealing with a potential risk factor for chronic neurological disorders. Journal of Neurology. https://doi.org/10.1007/s00415-020-10131-y

Smieszek, S. P., Przychodzen, B. P., & Polymeropoulos, M. H. (2020). Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. International Journal of Antimicrobial Agents, 55(6), 106004. https://doi.org/10.1016/j.ijantimicag.2020.106004

Sulzer, D., Antonini, A., Leta, V., Nordvig, A., Smeyne, R. J., Goldman, J. E., Al-Dalahmah, O., Zecca, L., Sette, A., Bubacco, L., Meucci, O., Moro, E., Harms, A. S., Xu, Y., Fahn, S., & Ray Chaudhuri, K. (2020). COVID-19 and possible links with Parkinson’s disease and parkinsonism: From bench to bedside. NPJ Parkinson’s Disease, 6, 18. https://doi.org/10.1038/s41531-020-00123-0

Sveinbjornsdottir, S. (2016). The clinical symptoms of Parkinson’s disease. Journal of neurochemistry, 139, 318–324. https://doi.org/10.1111/jnc.13691

Tarolli, C. G., Andrzejewski, K., Zimmerman, G. A., Bull, M., Goldenthal, S., Auinger, P., O’Brien, M., Dorsey, E. R., Biglan, K., & Simuni, T. (2020). Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-202163

Tipton, P. W., & Wszolek, Z. K. (2020). What can Parkinson’s disease teach us about COVID-19? Neurologia I Neurochirurgia Polska, 54(2), 204–206. https://doi.org/10.5603/PJNNS.a2020.0039

Torres, J., Maheswari, U., Parthasarathy, K., Ng, L., Liu, D. X., & Gong, X. (2007). Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein science, 16(9), 2065–2071. https://doi.org/10.1110/ps.062730007

Umemura, A., Oeda, T., Tomita, S., Hayashi, R., Kohsaka, M., Park, K., Sugiyama, H., & Sawada, H. (2014). Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: A nested case-control study. PloS one, 9(6), e94944. https://doi.org/10.1371/journal.pone.0094944

van der Heide, A., Meinders, M. J., Bloem, B. R., & Helmich, R. C. (2020). The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-202251

van Laar, T., & Borgemeester, R. (2016). The need for non-oral therapy in Parkinson’s disease; a potential role for apomorphine. Parkinsonism & related disorders, 33, S22–S27. https://doi.org/10.1016/j.parkreldis.2016.11.019

Wang, B., Li, R., Lu, Z., & Huang, Y. (2020). Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging (Albany NY), 12(7), 6049. https://doi.org/10.18632/aging.103000

WHO, W. H. O. (2020). Surveillance case definitions for human infection with novel coronavirus (‎‎‎ nCoV)‎‎‎: Interim guidance v1, January 2020. World Health Organization. https://apps.who.int/iris/handle/10665/330376

Xia, Y., Kou, L., Zhang, G., Han, C., Hu, J., Wan, F., Yin, S., Sun, Y., Wu, J., Li, Y., Zhang, Z., Huang, J., Xiong, N., & Wang, T. (2020). Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Medicine, 75, 428–433. https://doi.org/10.1016/j.sleep.2020.09.011

Zheng, K. S., Dorfman, B. J., Christos, P. J., Khadem, N. R., Henchcliffe, C., Piboolnurak, P., & Nirenberg, M. J. (2012). Clinical characteristics of exacerbations in Parkinson disease. The neurologist, 18(3), 120. https://dx.doi.org/10.1097%2FNRL.0b013e318251e6f2

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., & Gu, X. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The lancet. https://doi.org/10.1016/S0140-6736(20)30566-3

Zipprich, H. M., Teschner, U., Witte, O. W., Schönenberg, A., & Prell, T. (2020). Knowledge, Attitudes, Practices, and Burden During the COVID-19 Pandemic in People with Parkinson’s Disease in Germany. Journal of Clinical Medicine, 9(6). https://doi.org/10.3390/jcm9061643

Published

24/01/2021

How to Cite

PAIVA, . K. M. .; OLIVEIRA, R. F. .; ROCHA, G. S. da; MORAIS, P. L. A. de G. .; ARAÚJO, D. P. de; OLIVEIRA, L. C. de .; GUZEN, F. P. .; CAVALCANTI, J. R. L. de P. . Global impacts of COVID-19 infection in patients with Parkinson’s disease: an integrative review. Research, Society and Development, [S. l.], v. 10, n. 1, p. e47310112043, 2021. DOI: 10.33448/rsd-v10i1.12043. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/12043. Acesso em: 25 feb. 2021.

Issue

Section

Health Sciences